Publication:
Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

dc.contributor.authorDíez-Fuertes, Francisco
dc.contributor.authorLopez-Huertas, Maria Rosa
dc.contributor.authorGarcía-Pérez, Javier
dc.contributor.authorCalonge, Esther
dc.contributor.authorBermejo, Mercedes
dc.contributor.authorMateos, Elena
dc.contributor.authorMartí, Pilar
dc.contributor.authorMuelas, Nuria
dc.contributor.authorVílchez, Juan Jesús
dc.contributor.authorCoiras, Mayte
dc.contributor.authorAlcamí, José
dc.contributor.authorRodriguez Mora, Sara
dc.contributor.funderAgence Nationale de Recherches sur le sida et les hépatites virales (Francia)
dc.contributor.funderAsociación Conquistando Escaloneses_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderFundación Isabel Gemio
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.date.accessioned2022-07-01T09:00:09Z
dc.date.available2022-07-01T09:00:09Z
dc.date.issued2022-05-13
dc.description.abstractLGMDD2 is a rare form of muscular dystrophy characterized by one of the three heterozygous deletions described within the TNPO3 gene that result in the addition of a 15-amino acid tail in the C-terminus.TNPO3 is involved in the nuclear import of splicing factors and acts as a host cofactor for HIV-1 infection by mechanisms not yet deciphered. Further characterization of the crosstalk between HIV-1 infection and LGMDD2 disease may contribute to a better understanding of both the cellular alterations occurring in LGMDD2 patients and the role of TNPO3 in the HIV-1 cycle. To this regard, transcriptome profiling of PBMCs from LGMDD2 patients carrying the deletion c.2771delA in the TNPO3 gene was compared to healthy controls. A total of 545 differentially expressed genes were detected between LGMDD2 patients and healthy controls, with a high representation of G protein-coupled receptor binding chemokines and metallopeptidases among the most upregulated genes in LGMDD2 patients. Plasma levels of IFN-β and IFN-γ were 4.7- and 2.7-fold higher in LGMDD2 patients, respectively. An increase of 2.3-fold in the expression of the interferon-stimulated gene MxA was observed in activated PBMCs from LGMDD2 patients after ex vivo HIV-1 pseudovirus infection. Thus, the analysis suggests a pro-inflammatory state in LGMDD2 patients also described for other muscular dystrophies, that is characterized by the alteration of IL-17 signaling pathway and the consequent increase of metallopeptidases activity and TNF response. In summary, the increase in interferons and inflammatory mediators suggests an antiviral environment and resistance to HIV-1 infection but that could also impair muscular function in LGMDD2 patients, worsening disease evolution. Biomarkers of disease progression and therapeutic strategies based on these genes and mechanisms should be further investigated for this type of muscular dystrophy.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis study was funded by Asociación Conquistando Escalones, French Agency for Research on AIDS and Viral Hepatitis (ANRS grant ECTZ107263), Instituto de Salud Carlos III (PI19CIII/00004), NIH grant R01AI143567, the Spanish Ministry of Science and Innovation (PID2019-110275RB I00) and Fundación Isabel Gemio. It has been conducted within the Spanish AIDS Research Network (RIS) and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, funded by Instituto de Salud Carlos 640 III (Plan Estatal de I+D+I 2013-2016) and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (RD16CIII/0002/0001).es_ES
dc.format.page839813es_ES
dc.format.volume10es_ES
dc.identifier.citationFront Cell Dev Biol. 2022 May 13;10:839813.es_ES
dc.identifier.doi10.3389/fcell.2022.839813es_ES
dc.identifier.issn2296-634Xes_ES
dc.identifier.journalFrontiers in cell and developmental biologyes_ES
dc.identifier.pubmedID35646913es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14659
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-110275RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19CIII/00004es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fcell.2022.839813es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectHIV-1es_ES
dc.subjectLGMDD2es_ES
dc.subjectTranscriptomees_ES
dc.subjectChemokineses_ES
dc.subjectInflammation pathwayes_ES
dc.titleTranscriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infectiones_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication05199c38-bb50-4a79-bb3b-96dce9769920
relation.isAuthorOfPublicationcd13d2cc-b148-4e72-94f3-02e58c5e1abd
relation.isAuthorOfPublicatione4416b9d-e4ad-48e5-a0b6-e760b90bf5c5
relation.isAuthorOfPublication5427ef71-65f2-46b8-a759-ce3ee260702b
relation.isAuthorOfPublicationa391b61e-450a-44e5-bff8-96587441fd7b
relation.isAuthorOfPublication70d4b634-f13f-4b35-a47e-5a337f5acbfc
relation.isAuthorOfPublicationf729e106-ee5d-450a-b046-63b14e24c1a3
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublicationc5118ef8-1e9b-46a4-942e-1c8e2b363f57
relation.isAuthorOfPublication.latestForDiscovery05199c38-bb50-4a79-bb3b-96dce9769920
relation.isFunderOfPublication3d8259f8-cdd5-40c4-b268-251a4776ca62
relation.isFunderOfPublicationd863b318-3e6b-4cfc-81bb-a6d112b1f86e
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication103dc765-ed48-4f9c-bbe3-88575231aa8c
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication.latestForDiscovery3d8259f8-cdd5-40c4-b268-251a4776ca62
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
TranscriptomicEvidenceImmuneResponse_2022.pdf
Size:
3.2 MB
Format:
Adobe Portable Document Format
Description: